🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome

RecruitingPhase 4Ages 18 Years - 65 YearsAllKing Edward Medical University
NCT06765265 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

there will be 2 groups of patients with acute coronary syndrome. The patients will receive one of the 2 study drugs and impact on raising Vitamin D level will be seen after 6 months

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Acute Coronary Syndrome 25 OH-Vitamin D levels between 30-70ng/ml Exclusion Criteria: Hypercalcemia hypocalcemia pregnancy lactation hypersensitivity to statins hypothyroidism Deranged LFTs \& RFTs Use of following within last 3 months (Vitamin D Supplements, lipid lowering drugs, anti-obesity drugs, corticosteroids)
💊

What it tests

  • Rosuvastatin 20 mg/day
  • Atorvastatin 40 mg
📍

Where

1 site
King Edward Medical University
Lahore, Pakistan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy